title: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
abstract: Previous studies of attenuated simian immunodeficiency virus (SIV) vaccines in rhesus macaques have demonstrated the development of broad protection against experimental challenge, indicating the potential for the production of highly effective immune responses to SIV antigens. However, the development of this protective immune status was found to be critically dependent on the length of time postvaccination with the attenuated virus strain, suggesting a necessary maturation of immune responses. In this study, the evolution of SIV envelope-specific antibodies in monkeys experimentally infected with various attenuated strains of SIV was characterized by using a comprehensive panel of serological assays to assess the progression of antibodies in longitudinal serum samples that indicate the development of protective immunity. In parallel studies, we also used the same panel of antibody assays to characterize the properties of SIV envelope-specific antibodies elicited by inactivated whole-virus and envelope subunit vaccines previously reported to be ineffective in producing protective immunity. The results of these studies demonstrate that the evolution of protective immunity in monkeys inoculated with attenuated strains of SIV is associated with a complex and lengthy maturation of antibody responses over the first 6 to 8 months postinoculation, as reflected in progressive changes in antibody conformational dependence and avidity properties. The establishment of long-term protective immunity at this time in general parallels the absence of further detectable changes in antibody responses and a maintenance of relatively constant antibody titer, avidity, conformational dependence, and the presence of neutralizing antibody for at least 2 years postinoculation. In contrast to the mature antibody responses elicited by the attenuated SIV vaccines, the whole-virus and envelope subunit vaccines in general elicited only immature antibody responses characterized by poor reactivity with native envelope proteins, low avidity, low conformational dependence, and the absence of neutralization activity against the challenge strain. Thus, these studies establish for the first time an association between the effectiveness of experimental vaccines and the capacity of the vaccine to produce a mature antibody response to SIV envelope proteins and further indicate that a combination of several antibody parameters (including titer, avidity, conformational dependence, and virus neutralization) are superior to any single antibody parameter as prognostic indicators to evaluate candidate AIDS vaccines.
authors.affiliation: Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pennsylvania 15261, USA.
authors.forename: K S
authors.initials: KS
authors.lastname: Cole
authors.forename: J L
authors.initials: JL
authors.lastname: Rowles
authors.forename: B A
authors.initials: BA
authors.lastname: Jagerski
authors.forename: M
authors.initials: M
authors.lastname: Murphey-Corb
authors.forename: T
authors.initials: T
authors.lastname: Unangst
authors.forename: J E
authors.initials: JE
authors.lastname: Clements
authors.forename: J
authors.initials: J
authors.lastname: Robinson
authors.forename: M S
authors.initials: MS
authors.lastname: Wyand
authors.forename: R C
authors.initials: RC
authors.lastname: Desrosiers
authors.forename: R C
authors.initials: RC
authors.lastname: Montelaro
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D002478:Cells, Cultured; D017353:Gene Deletion; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008253:Macaca mulatta; D008562:Membrane Glycoproteins / Q000276:immunology*; D012191:Retroviridae Proteins / Q000276:immunology*; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D008562:Membrane Glycoproteins; D012191:Retroviridae Proteins; D018449:SAIDS Vaccines; C080347:SIV envelope protein gp110; C082614:SIV envelope protein gp41; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins